Algert Global LLC Grows Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Algert Global LLC increased its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 25.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 20,642 shares of the company’s stock after purchasing an additional 4,170 shares during the period. Algert Global LLC’s holdings in Omnicell were worth $919,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of OMCL. Vanguard Group Inc. boosted its holdings in Omnicell by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company’s stock valued at $247,628,000 after acquiring an additional 28,573 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Omnicell by 31.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company’s stock worth $73,127,000 after purchasing an additional 394,820 shares in the last quarter. Victory Capital Management Inc. grew its holdings in shares of Omnicell by 32.9% in the fourth quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company’s stock valued at $67,951,000 after purchasing an additional 377,883 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in Omnicell by 93.3% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company’s stock worth $64,573,000 after buying an additional 699,925 shares during the period. Finally, ArrowMark Colorado Holdings LLC increased its stake in Omnicell by 4.9% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 1,196,990 shares of the company’s stock worth $53,290,000 after buying an additional 56,117 shares during the period. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Trading Up 1.9 %

NASDAQ:OMCL opened at $25.88 on Friday. Omnicell, Inc. has a 1 year low of $22.66 and a 1 year high of $55.75. The stock has a market cap of $1.21 billion, a P/E ratio of 95.86, a P/E/G ratio of 7.53 and a beta of 0.78. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The stock has a 50-day simple moving average of $32.28 and a 200-day simple moving average of $39.96.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.16 by $0.10. The company had revenue of $269.67 million for the quarter, compared to analyst estimates of $260.18 million. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. The firm’s revenue was up 9.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.03 earnings per share. As a group, analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

OMCL has been the subject of several research reports. JPMorgan Chase & Co. dropped their price target on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a research note on Thursday, March 20th. Wells Fargo & Company lowered their target price on Omnicell from $38.00 to $31.00 and set an “equal weight” rating for the company in a research note on Wednesday. StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a research report on Saturday, May 3rd. Finally, Benchmark lowered their price objective on Omnicell from $62.00 to $40.00 and set a “buy” rating for the company in a research report on Wednesday. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, Omnicell has an average rating of “Hold” and a consensus price target of $45.83.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.